Research programme: histamine H3 receptor antagonists - UCBAlternative Names: H3R antagonists - UCB
Latest Information Update: 16 Jul 2016
At a glance
- Originator UCB
- Mechanism of Action Histamine H3 receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Cognition disorders
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cognition-disorders in Europe (Injection)
- 06 Nov 2006 Preclinical trials in Cognition disorders in Europe (Injection)